Article Text

This article has a correction. Please see:

Download PDFPDF
Polyethylene glycol 3350 plus electrolytes for chronic constipation in children: a double blind, placebo controlled, crossover study
  1. M A Thomson1,
  2. H R Jenkins2,
  3. W M Bisset3,
  4. R Heuschkel4,
  5. D S Kalra5,
  6. M R Green6,
  7. D C Wilson7,
  8. M Geraint8
  1. 1
    Centre for Paediatric Gastroenterology, Sheffield Children’s Hospital, Sheffield, UK
  2. 2
    Department of Child Health, University Hospital of Wales, Cardiff, UK
  3. 3
    Department of Paediatric Gastroenterology, Royal Aberdeen Children’s Hospital, Aberdeen, UK
  4. 4
    Centre for Paediatric Gastroenterology, Royal Free Hospital, London, UK
  5. 5
    Royal Wolverhampton Hospitals NHS Trust, New Cross Hospital, Wolverhampton, UK
  6. 6
    Children’s Hospital, University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, Leicester, UK
  7. 7
    Paediatric Gastroenterology and Nutrition Department, Royal Hospital for Sick Children, Edinburgh, and Child Life and Health, University of Edinburgh, Edinburgh, UK
  8. 8
    Norgine Ltd, Harefield, Middlesex, UK
  1. M Thomson, Centre for Paediatric Gastroenterology, Sheffield Children’s Hospital, Western Bank, Sheffield S10 2TH, UK; Mike.Thomson{at}


Objectives: To assess the efficacy and safety of polyethylene glycol 3350 plus electrolytes (PEG+E) for the treatment of chronic constipation in children.

Design: Randomised, double blind, placebo controlled crossover trial, with two 2-week treatment periods separated by a 2-week placebo washout.

Setting: Six UK paediatric departments.

Participants: 51 children (29 girls, 22 boys) aged 24 months to 11 years with chronic constipation (lasting ⩾3 months), defined as ⩽2 complete bowel movements per week and one of the following: pain on defaecation on 25% of days; ⩾25% of bowel movements with straining; ⩾25% of bowel movements with hard/lumpy stools. 47 children completed the double blind treatment.

Main outcome measures: Number of complete defaecations per week (primary efficacy variable), total number of complete and incomplete defaecations per week, pain on defaecation, straining on defaecation, faecal incontinence, stool consistency, global assessment of treatment, adverse events and physical examination.

Results: The mean number of complete defaecations per week was significantly higher for children on PEG+E than on placebo (3.12 (SD 2.05) v 1.45 (SD 1.20), respectively; p<0.001). Further significant differences in favour of PEG+E were observed for total number of defaecations per week (p = 0.003), pain on defaecation (p = 0.041), straining on defaecation (p<0.001), stool consistency (p<0.001) and percentage of hard stools (p = 0.001). Treatment related adverse events (all mild or moderate) occurred in similar numbers of children on PEG+E (41%) and placebo during treatment (45%).

Conclusions: PEG+E is significantly more effective than placebo, and appears to be safe and well tolerated in the treatment of chronic constipation in children.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding: This study was funded by Norgine Ltd.

  • Competing interests: Dr Mike Geraint is an employee of Norgine Ltd. All other authors declare that they have nothing to declare.

  • Ethics approval: This study was approved by the London Multi-Centre Research Ethics Committee and the appropriate local research ethics committees. It was conducted in compliance with the protocol (Norgine 2000/01) and according to the ethical principles stated in the latest version of the Declaration of Helsinki, the applicable ICH guidelines for good clinical practice, and UK regulatory requirements.

  • Abbreviations:
    analysis of variance
    95% CI
    95% confidence interval
    intention to treat
    polyethylene glycol 3350 plus electrolytes
    per protocol
    standard deviation

Linked Articles

  • Atoms
    Howard Bauchner, Editor-in-Chief
  • Corrections
    BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health